التفاصيل البيبلوغرافية
| العنوان: |
Abstract 11650: Cardiometabolic Disease Protein Signatures and Response to GLP-1 Receptor Agonist in the EXSCEL Clinical Trial |
| المؤلفون: |
Ostroff, Rachel, Green, Jennifer, Mentz, Robert J, Chadwick, Jessica, Hinterberg, Michael, Kureshi, Natasha, Simpson, Missy, Williams, Stephen A, Hernandez, Adrian F, Holman, Rury, Sattar, Naveed, Shah, Svati H |
| المصدر: |
Circulation ; volume 146, issue Suppl_1 ; ISSN 0009-7322 1524-4539 |
| بيانات النشر: |
Ovid Technologies (Wolters Kluwer Health) |
| سنة النشر: |
2022 |
| الوصف: |
Introduction: Recent type 2 diabetes (T2D) therapeutics have pleiotropic benefits. High throughput proteomic assays offer opportunities to systematically analyze T2D-related cardiometabolic traits and drug-related effects. Methods: The Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial randomized patients with T2D to once-weekly exenatide (EQW) versus placebo. This biomarker substudy of 5205 participants performed plasma proteomic profiling on baseline and 1-year samples using an aptamer-based platform. Changes in nine protein-imputed cardiometabolic traits were compared between treatment groups. In exploratory analyses, proteomic cardiovascular (CV) risk was stratified in individuals based on use of open label “drop-in” SGLT-2 inhibitors during follow-up. Results: Proteomic signatures for impaired glucose tolerance, body fat, and visceral fat decreased more in the EQW group compared with placebo (adjusted p<0.05), partially consistent with EQW-induced weight loss ( Figure ). Protein-imputed resting energy rate, cardiorespiratory fitness, and lean body mass also decreased to a greater extent in the EQW group. Proteomic CV risk increased in both groups over one year but increased less in the EQW group (0.8% vs. 2.3%, adjusted p<0.01). Individuals predicted at baseline to be at high CV risk had significantly lower observed CV event rates if they received “drop-in” SGLT-2 inhibitors (p<0.05). Conclusion: Leveraging EXSCEL, a large-scale clinical trial of a GLP1-receptor agonist, this biomarker substudy uses proteomic signatures to demonstrate pleiotropic drug effects related to cardiometabolic traits. Further, proteomic CV risk increased to a lesser extent in individuals randomized to EQW, suggesting that EQW has beneficial effects influencing cardiovascular risk directly or indirectly through these proteomic pathways. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1161/circ.146.suppl_1.11650 |
| الإتاحة: |
https://doi.org/10.1161/circ.146.suppl_1.11650Test |
| رقم الانضمام: |
edsbas.274DC690 |
| قاعدة البيانات: |
BASE |
